Project Management | Relationship Management | Clinical Research and RWE Technology | Johns Hopkins DrPH 2024 Cohort
ICYMI living in an underground bunker since 2020, the vaccine market is hot hot hotter than ever. In pursuit of being the first to market, vaccine study startup can feel like a game of "Name that Tune", especially when it comes to data collection. I can deploy that solution in 6 weeks; I can deploy it in 4 weeks! But when it comes to electronic data collection, faster isn't always better. As someone with years of experience in eCOA for vaccine trials, I've seen firsthand the impact of rushed delivery. While it may seem like the shortest possible timeline provides the biggest value to sponsors, it often creates quality issues down the line. These issues impact everyone involved in the trial, from participants to site and monitoring teams to vendors, and the sponsor team themselves. That's why it's important to take a more nuanced approach to evaluating technology implementation in trials. By analyzing a broader range of implementation metrics and developing a coherent story, we can justify more methodical and measured development and deployment. And by training staff in every client-facing function on how to message this value proposition consistently, we challenge the dogma that faster is always better. So let's take the time to get it right and prioritize quality over speed. Because in the long run, that's what will truly make a difference in the participant experience, the data quality, and speed to market. #VaccineTrials #ClinicalResearch #eCOA #QualityOverSpeed
Clinical Operations and Development Manager at Sage Therapeutics
9moWell said - I couldn't agree more!